Please select the option that best describes you:
Topics:
Genitourinary Cancers • Medical Oncology
Would you use apalutamide in high risk non-metastatic castrate resistant prostate cancer?
The recent SPARTAN trial showed a remarkable improvement in metastasis free survival and many other secondary endpoints except the lack of significant benefit in OS, which may be related to the immaturity of the data at this time.
Answer from: Medical Oncologist at Academic Institution
I would consider using apalutamide for the appropriate patient, which I would define as meeting the entry criteria for the study i.e. PSA DT 10 months or less. The label for the drug is broad i.e. any castration resistant PSA only patient, which I beleive is too far to inclusive, many of ...
Sign in or Register to read more